Alligator Bioscience

Declaration of Voting Results & Voting Rights Announcements • Jun 30, 2023

CHANGE IN NUMBER OF SHARES AND VOTES IN ALLIGATOR BIOSCIENCE AB

During June 2023, the number of shares and votes in Alligator Bioscience AB ("Alligator") has increased as a result of the completion of the rights issue of units which was resolved by the Board of Directors on 22 March 2023 and approved by the Extraordinary General Meeting held on 24 April 2023. As of 30 June 2023, the total number of outstanding shares in Alligator amounts to 624,525,669, whereof 623,575,819 are ordinary shares with one vote each and 949,850 are series C shares with 1/10 vote each. The total number of votes as of 30 June 2023 amounts to 623,670,804.

For further information, please contact:

Søren Bregenholt, CEO E-mail: soren.bregenholt@alligatorbioscience.com Phone: +46 (0) 46 540 82 00

This information is information that Alligator Bioscience is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-06-30 08:30 CEST.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumordirected immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

Change in number of shares and votes in Alligator Bioscience AB